Phospholipids profiling and outcome of peritoneal dialysis patients

Biomarkers

Volumn 19, Issue 6, 2014, Pages 505-508

  Tang, Wen ^a   Li, Min ^b   Lu, Xin Hong ^a   Liu, Hu Wei ^b   Wang, Tao ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Lipidomics; Mass spectrometry; Peritoneal dialysis; Phospholipids; Sphingomyelin

Indexed keywords

ALBUMIN; CALCIUM; CREATININE; GLYCEROPHOSPHORYLCHOLINE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID; POTASSIUM; SPHINGOMYELIN; TRIACYLGLYCEROL; UREA; PHOSPHATIDYLCHOLINE;

ACUTE HEART INFARCTION; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART FAILURE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MALE; NEOPLASM; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PHOSPHOLIPID BLOOD LEVEL; PNEUMONIA; POTASSIUM BLOOD LEVEL; SURVIVAL; TIME OF FLIGHT MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; AGED; BLOOD; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PHOSPHATIDYLCHOLINES; PROPORTIONAL HAZARDS MODELS; SPHINGOMYELINS;

EID: 84906330596     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.943290     Document Type: Article

References (23)

1. Folch J, Lees M, Sloane Stanley GH. (1957). A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
2. Forrester JS, Milne SB, Ivanova PT, Brown HA. (2004). Computational lipidomics: a multiplexed analysis of dynamic changes in membrane lipid composition during signal transduction. Mol Pharmacol 65: 813-21.
3. Friedman AN, Yu Z, Denski C, et al. (2013). Fatty acids and other risk factors for sudden cardiac death in patients starting hemodialysis. Am J Nephrol 38:12-18.
4. Hla, T, Dannenberg AJ. (2012). Sphingolipid signaling in metabolic disorders. Cell Metab 16:420-34.
5. Jia L, Wang C, Kong H, et al. (2007a). Effect of PA-MSHA vaccine on plasma phospholipids metabolic profiling and the ratio of Th2/Th1 cells within immune organ of mouse IgA nephropathy. J Pharm Biomed Anal 43:646-54.
6. Jia L, Wang C, Zhao S, et al. (2007b). Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 860:134-40.
7. Lam, SM, Shui G. (2013). Lipidomics as a principal tool for advancing biomedical research. J Genet Genomics 40:375-90.
8. Lee S, Lee YS, Choi KM, et al. (2012). Quantitative analysis of sphingomyelin by high-performance liquid chromatography after enzymatic hydrolysis. Evid Based Complement Alternat Med 2012: Article ID 396218, 9 pages.
9. Lee YK, Lee DH, Kim JK, et al. (2013). Lysophosphatidylcholine, oxidized low-density lipoprotein and cardiovascular disease in Korean hemodialysis patients: analysis at 5 years of follow-up. J Korean Med Sci 28:268-73.
10. Li M, Feng B, Liang Y, et al. (2013). Lipid profiling of human plasma from peritoneal dialysis patients using an improved 2D (NP/RP) LC-QToF MS method. Anal Bioanal Chem 405:6629-38.
11. Liu R, Peng Y, Li X, et al. (2013). Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform. Int J Mol Sci 14:8899-911.
12. Makinen VP, Tynkkynen T, Soininen P, et al. (2012). Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics 8:369-75.
13. Nicolson GL, Ash ME. (2014). Lipid Replacement Therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function. Biochim Biophys Acta 1838:1657-79.
14. Niwa T. (2008). Biomarker discovery for kidney diseases by mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 870: 148-53.
15. Obinata H, Hla T. (2012). Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol 34:73-91.
16. Oursel D, Loutelier-Bourhis C, Orange N, et al. (2007). Lipid composition of membranes of Escherichia coli by liquid chromatography/ tandem mass spectrometry using negative electrospray ionization. Rapid Commun Mass Spectrom 21:1721-8.
17. Pavoine C, Pecker F. (2009). Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 82: 175-83.
18. Pulfer M, Murphy RC. (2003). Electrospray mass spectrometry of phospholipids. Mass Spectrom Rev 22:332-64.
19. Stegemann C, Pechlaner R, Willeit P, et al. (2014). Lipidomics profiling and risk of cardiovascular disease in the prospective population-based bruneck study. Circulation 129:1821-31.
20. Van Meer G, De Kroon AI. (2011). Lipid map of the mammalian cell. J Cell Sci 124:5-8.
21. Wymann MP, Schneiter R. (2008). Lipid signalling in disease. Nat Rev Mol Cell Biol 9:162-76.
22. Yang WL, Bai Q, Li DD, et al. (2013). Changes of urinary phospholipids in the chronic kidney disease patients. Biomarkers 18:601-6.
23. Zhu C, Liang QL, Hu P, et al. (2011). Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta 85:1711-20.